Significance of serum Myostatin in hemodialysis patients

Esposito, Pasquale; Battaglia, Yuri; Porta, Edoardo La; Grignano, Maria Antonietta; Caramella, Elena; Avella, Alessando; Peressini, Sabrina; Sessa, Nicodemo; Albertini, Riccardo; Natali, Giuseppe Di; Lisi, Cláudio Sérgio; Gregorini, Marilena; Rampino, Teresa

doi:10.1186/s12882-019-1647-9

Cited by 13 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These parameters were associated with first-year mortality in univariate analysis but their effect was non-significant when adjusted for prealbumin [30]. Similar results were obtained in a subsequent study [31]. The use of a single marker may not be sufficient.…”

Section: Plos Onesupporting

confidence: 71%

Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients

Aniort

Freist

Piraud³

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Protein energy wasting (PEW) including muscle atrophy is a common complication in chronic hemodialysis patients. The ubiquitin proteasome system (UPS) is the main proteolytic system causing muscle atrophy in chronic kidney disease and proteasome 20S is the catalytic component of the UPS. Circulating proteasome 20S (c20S proteasome) is present in the blood and its level is related to disease severity and prognosis in several disorders. We hypothesized that c20S proteasome could be related with muscle mass, other PEW criteria and their evolution in hemodialysis patients. Stable hemodialysis patients treated at our center for more than 3 months were followed over 2 years. C20S proteasome assay was performed at baseline. Biological and clinical data were collected, muscle mass was assessed by multi-frequency bio-impedancemetry, and nutritional scores were calculated at baseline, 1 year and 2 years. Hospitalizations and mortality data were collected over the 2 years. Forty-nine patients were included. At baseline, the c20S proteasome level was 0.40 [0.26-0.55] μg/ml. Low muscle mass as defined by a lean tissue index (LTI) < 10th in accordance with the International Society of Renal Nutrition and Metabolism guidelines was observed in 36% and PEW in 62%. Increased c20S proteasome levels were related with LTI at baseline (R = 0.43, p = 0.004) and with its 2 year-variation (R =-0.56, p = 0.003). Twoyear survival rate was not different between higher and lower c20S proteasome values (78.9 vs 78.4%, p = 0.98 log-rank test). C20S proteasome is not a good marker for assessing nutritional status in hemodialysis patients and predicting patient outcomes.

show abstract

Section: Plos Onesupporting

confidence: 71%

Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients

Aniort

Freist

Piraud³

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…It seems unclear how chronic hemodialysis (HD) and its method affect serum myostatin levels. Contrary to research by Koyun et al, presenting an elevated serum myostatin level in chronic hemodialysis patients compared to healthy controls [ 91 ], two other studies showed no difference between these groups [ 181 , 182 ]. Esposito et al, noticed a significant decrease of plasma myostatin (associated by the authors with improvement of malnutrition status) after online hemodiafiltration (HDF) with no changes after bicarbonate hemodialysis (BHD) [ 181 ], while further studies showed a significant and comparable decrease of plasma myostatin levels after HD and HDF, and HDF and BHD, accordingly [ 84 , 182 ].…”

Section: Factors Affecting Myostatin Concentrationmentioning

confidence: 65%

Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps

2020

View full text Add to dashboard Cite

Sarcopenia is a geriatric syndrome with a significant impact on older patients’ quality of life, morbidity and mortality. Despite the new available criteria, its early diagnosis remains difficult, highlighting the necessity of looking for a valid muscle wasting biomarker. Myostatin, a muscle mass negative regulator, is one of the potential candidates. The aim of this work is to point out various factors affecting the potential of myostatin as a biomarker of muscle wasting. Based on the literature review, we can say that recent studies produced conflicting results and revealed a number of potential confounding factors influencing their use in sarcopenia diagnosing. These factors include physiological variables (such as age, sex and physical activity) as well as a variety of disorders (including heart failure, metabolic syndrome, kidney failure and inflammatory diseases) and differences in laboratory measurement methodology. Our conclusion is that although myostatin alone might not prove to be a feasible biomarker, it could become an important part of a recently proposed panel of muscle wasting biomarkers. However, a thorough understanding of the interrelationship of these markers, as well as establishing a valid measurement methodology for myostatin and revising current research data in the light of new criteria of sarcopenia, is needed.

show abstract

“…[ 4,5,[29][30][31]. Furthermore, serum myostatin is increased in sarcopenia associated with end-stage renal disease [6,7]. Our study included a whole-body estimate of muscle mass from bioimpedance and direct quantification of left quadriceps muscle volume.…”

Section: Myostatin Muscle Mass and Physical Fitnessmentioning

confidence: 99%

“…Absence or blockage of myostatin increases muscle mass and reduces adipose tissue volume [1,4]. However, these functions of myostatin have mainly been investigated in mouse models and human subjects with specific genetic mutations or severe concomitant conditions, such as end-stage renal disease [1,[4][5][6][7]. Data from healthy human subjects is still inconclusive.…”

Section: Introductionmentioning

confidence: 99%

Association of Serum Myostatin with Body Weight, Visceral Fat Volume, and High Sensitivity C-Reactive Protein But Not With Muscle Mass and Physical Fitness in Premenopausal Women

Kern-Matschilles

Gar

Wanger

et al. 2021

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Background The myokine myostatin regulates muscle mass and has been linked to insulin resistance and metabolic syndrome. However, data on its role in humans is still limited. We, therefore, investigated the associations of serum myostatin with muscle mass, physical fitness, and components of the metabolic syndrome in a cohort of premenopausal women. Methods We undertook a cross-sectional analysis of 233 women from the monocenter study PPSDiab, conducted in Munich, Germany. Participants had recently completed a pregnancy with or without gestational diabetes. Our analysis included medical history, anthropometrics, oral glucose tolerance testing, laboratory chemistry, cardiopulmonary exercise testing, and magnetic resonance imaging (n=142) of visceral fat volume, left quadriceps muscle mass, and muscle fat content. Serum myostatin was quantified by a competitive enzyme-linked immunosorbent assay. Results We observed positive correlations of serum myostatin with body mass index (ρ=0.235; p=0.0003), body fat percentage (ρ=0.166; p=0.011), waist circumference (ρ=0.206; p=0.002), intraabdominal fat volume (ρ=0.182; p=0.030) and high-sensitivity C-reactive protein (ρ=0.175; p=0.008). These correlations were reproduced in linear regression analyses with adjustment for age and time after delivery. We saw no correlations with muscle mass, physical fitness, insulin sensitivity, triglycerides, HDL cholesterol, and blood pressure. Conclusions Our observation of elevated serum myostatin in women with a higher body fat percentage, visceral obesity, and elevated c-reactive protein suggests that this myokine contributes to the altered muscle-adipose tissue crosstalk in metabolic syndrome. Elevated myostatin may advance this pathophysiologic process and could also impair the efficacy of exercise interventions. Further mechanistic studies, therefore, seem warranted.

show abstract

Significance of serum Myostatin in hemodialysis patients

Cited by 13 publications

References 36 publications

Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients

Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients

Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps

Association of Serum Myostatin with Body Weight, Visceral Fat Volume, and High Sensitivity C-Reactive Protein But Not With Muscle Mass and Physical Fitness in Premenopausal Women

Contact Info

Product

Resources

About